Anzeige
Mehr »
Freitag, 29.08.2025 - Börsentäglich über 12.000 News
Megatrend Uran: Die Nachfrage nach Uran explodiert - greift jetzt Buffetts Erfolgsrezept?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BV8 | ISIN: US2498455045 | Ticker-Symbol:
NASDAQ
29.08.25 | 21:59
5,640 US-Dollar
+7,43 % +0,390
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DERMATA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DERMATA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DERMATA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoDermata Therapeutics, Inc. - 8-K, Current Report1
13.08.Dermata Therapeutics, Inc. - 10-Q, Quarterly Report2
13.08.Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results280- Dermata announced additional positive data from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial-- Raised $8.8 million in gross proceeds from a private placement and...
► Artikel lesen
DERMATA THERAPEUTICS Aktie jetzt für 0€ handeln
13.08.Dermata Therapeutics, Inc. - 8-K, Current Report2
30.07.Dermata Therapeutics, Inc. - 8-K, Current Report1
16.07.Aktionäre von Dermata Therapeutics genehmigen Reverse Stock Split und wichtige Anträge6
08.07.Dermata Therapeutics: Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis459- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial...
► Artikel lesen
07.07.Dermata Therapeutics, Inc. - 8-K, Current Report1
05.06.Dermata Therapeutics, Inc. - 8-K, Current Report2
21.05.Dermata Therapeutics, Inc. - 8-K, Current Report1
14.05.Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results286- Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints -- Dermata entered into a Clinical...
► Artikel lesen
14.05.Dermata Therapeutics, Inc. - 8-K, Current Report5
14.05.Dermata Therapeutics, Inc. - 10-Q, Quarterly Report2
15.04.Dermata Therapeutics files to sell 10.01M shares of common stock for holders1
15.04.Dermata meldet frühen Erfolg bei Aknebehandlung mit XYNGARI3
15.04.Dermata reports early success in acne treatment with XYNGARI2
15.04.Dermata Therapeutics: Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks332- Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that XYNGARI...
► Artikel lesen
15.04.Dermata Therapeutics, Inc. - 8-K, Current Report2
28.03.Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules484SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...
► Artikel lesen
27.03.Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne2
Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1